ABMC Granted U.S. Patent for Lateral Flow Immunoassay Device; Covers Expanding Saliva Diagnostics Product Line.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ: ABMC) announced today that they have been granted a patent from the United States Patent and Trademark Office related to the Company's existing and future products in the area of saliva diagnostics.

The issued patent, U.S. Patent number 7,090,803, is directed to lateral flow immunoassay test devices that need treatment and incubation to the samples to get a meaningful result. Samples might include saliva, urine, blood, plasma, serum, or cerebral spinal fluid.

ABMC Chief Scientific Officer Martin Gould stated: "We are very aware of the growing importance of being able to test for drugs of abuse and other various disease states in oral fluids. This particular patent is the first to be issued in a series that we have applied for to the U.S. Patent and Trademark office related to saliva diagnostics. Our R&D team is committed to making continuous breakthroughs in oral fluid testing, not only including our current drugs of abuse product line, but in infectious disease such as HIV. "

ABMC Chief Executive Officer Stan Cipkowski said: "Our OralStat test for drugs of abuse is the most sensitive and accurate of any point of care saliva test on the market. Some of the world's largest staffing and retail companies are using this product and have already committed to increasing its use in the coming months. As we have established with our previous products, ABMC intends to be the industry leader in the development of oral fluids point of care tests."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One, Rapid TEC(R), RDS(R) InCup(R) and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.